Orphagen Pharmaceuticals
  • Home
  • Team
  • Pipeline
    • Pipeline
    • OR-449 for Oncology
    • OR-812 for IBD
    • RORβ Antagonists
  • Our Science
  • News
  • Contact
Select Page

ORPHAGEN PHARMACEUTICALS AWARDED SBIR PHASE II GRANT TO INVESTIGATE RETINOIC ACID ANTAGONISTS AS MALE CONTRACEPTIVES

by Orphagen Pharma | Sep 1, 2019 | News

Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has awarded the company $1.8 million under the Small Business Innovation Research (SBIR)...

News Archives

Search the Archives

Orphagen Pharmaceuticals, Inc.

9276 Sorrento Valley Rd
Suite 500
San Diego, CA 92121

For inquiries please contact info@orphagen.com

Designed by Elegant Themes | Powered by WordPress